Owens Gary M

Owens, then-CEO of MLAB, sold 21,000 shares ($2.6M) on 2025-03-19 via pre-arranged 10b5-1 plan.

Gary M Owens, who held the title of President and CEO at the time of this transaction, sold 21,000 shares at $123.91 on 2025-03-19 as part of a pre-arranged 10b5-1 trading plan adopted on 2024-09-12. This scheduled sale reduced his holdings from 64,337 shares to 43,337 shares, a -32.6% reduction in his position. Since the trade was governed by a pre-arranged plan rather than executed at the executive's discretion, it reflects a contractual obligation established months earlier and carries no timing signal regarding near-term business outlook. The substantial reduction in holding size—from 64.3K to 43.3K shares—warrants scrutiny into whether the 10b5-1 plan parameters or adoption timing reflected any material considerations at the time of plan establishment in September 2024.

MLAB CEO Gary M Owens sells 5,069 shares for $571,735.87 at blended avg $112.79

Gary M Owens, President and CEO, sold 5,069 shares of MESA LABORATORIES across two separate transactions on 2024-10-28 and 2024-10-29 for a blended average price of $112.79. The sale reduced his holdings by 10.5%, from 48.4K to 43.3K shares, totaling $571,735.87. This occurs in a context where the company has negative full-year net income, annual revenue is flat to declining (-1.3%), and the stock is down 20.0% from its 52-week high of $140.86. The sale occurs at prices ($113.62 and $111.98) near the current market price of $112.68, providing no clear signal about insider timing confidence given the stock's broader 52-week range and recent weakness.